

# Measuring quality of life in men with prostate cancer using the Cancer Therapy-prostate instrument

Urology

50, 920-928

DOI: [10.1016/s0090-4295\(97\)00459-7](https://doi.org/10.1016/s0090-4295(97)00459-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life in men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 1998, 1, 228-235.	2.0	6
2	Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. , 1998, 69, 156-161.		32
3	Systemic treatment for prostate cancer. <i>Cancer Treatment Reviews</i> , 1998, 24, 283-301.	3.4	35
4	QUALITY OF LIFE IN METASTATIC PROSTATE CANCER AMONG MEN OF LOWER SOCIOECONOMIC STATUS: FEASIBILITY AND CRITERION RELATED VALIDITY OF 3 MEASURES. <i>Journal of Urology</i> , 1998, 160, 1765-1769.	0.2	34
5	Opportunities and Challenges: Assessing Quality of Life in Clinical Trials. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1498-1499.	3.0	4
6	Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1537-1544.	3.0	152
7	Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1664-1664.	0.8	158
8	A new concept in cancer care: The supportive care program. <i>American Journal of Hospice and Palliative Medicine</i> , 1999, 16, 713-722.	0.8	19
9	Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. <i>Quality of Life Research</i> , 1999, 8, 181-195.	1.5	374
10	Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. <i>Quality of Life Research</i> , 1999, 8, 461-470.	1.5	24
11	Examining health-related quality of life in men treated for prostate cancer. <i>World Journal of Urology</i> , 1999, 17, 205-210.	1.2	10
13	Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. <i>Cancer</i> , 1999, 86, 1793-1801.	2.0	44
14	Defining an international research agenda for quality of life in men with prostate cancer. , 1999, 41, 58-67.		27
15	Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. <i>Radiation Oncology Investigations</i> , 1999, 7, 178-185.	1.3	86
16	A Review of Quality-of-Life Evaluations in Prostate Cancer. <i>Pharmacoeconomics</i> , 1999, 16, 127-140.	1.7	34
17	Convergent Discriminative, and Predictive Validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Assessment and Comparison with Analogous Scales From the EORTC QLQ-C30 and a Trial-Specific Module. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 653-666.	2.4	59
18	EARLY QUALITY OF LIFE ASSESSMENT IN MEN TREATED WITH PERMANENT SOURCE INTERSTITIAL BRACHY THERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 1999, 162, 403-406.	0.2	60
19	RECOVERY OF HEALTH RELATED QUALITY OF LIFE IN THE YEAR AFTER RADICAL PROSTATECTOMY: EARLY EXPERIENCE. <i>Journal of Urology</i> , 1999, 161, 515-519.	0.2	120

#	ARTICLE	IF	CITATIONS
20	PC-SPEs, a dietary supplement for the treatment of hormone-refractory prostate cancer. <i>BJU International</i> , 2000, 85, 481-485.	1.3	86
21	A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 77-81.	0.4	62
22	Quality of life following prostate cancer treatments. <i>Current Urology Reports</i> , 2000, 1, 71-77.	1.0	6
23	Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. <i>Urology</i> , 2000, 56, 899-905.	0.5	1,331
24	Patient-Clinician Choice in Palliation of Metastatic Prostate Cancer. <i>Drugs and Aging</i> , 2000, 17, 331-337.	1.3	1
25	HEALTH RELATED QUALITY OF LIFE ASSESSMENT AFTER RADICAL PROSTATECTOMY IN MEN WITH PROSTATE SPECIFIC ANTIGEN ONLY RECURRENCE. <i>Journal of Urology</i> , 2001, 166, 2286-2290.	0.2	30
26	Quality of life in patients with prostate cancer. <i>Seminars in Oncology Nursing</i> , 2001, 17, 138-146.	0.7	17
27	Quality of Life endpoints in prostate chemoprevention trials. <i>Urology</i> , 2001, 57, 235-240.	0.5	14
28	CLINICAL CONDUCT AND NURSING QUALITY OF LIFE IN PROSTATE CANCER. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 573-581.	0.9	0
29	OUTPATIENT RADICAL PROSTATECTOMY: IMPACT OF STANDARD PERINEAL APPROACH ON PATIENT OUTCOME. <i>Journal of Urology</i> , 2001, 166, 581-586.	0.2	71
30	COMPARISON OF PATIENT AND SPOUSE ASSESSMENTS OF HEALTH RELATED QUALITY OF LIFE IN MEN WITH METASTATIC PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 165, 478-482.	0.2	46
31	Social Support for Patients with Prostate Cancer. <i>Journal of Psychosocial Oncology</i> , 2001, 19, 1-16.	0.6	19
32	Reliability and Validity of the Functional Assessment of Cancer Therapy—Ovarian. <i>Journal of Clinical Oncology</i> , 2001, 19, 1809-1817.	0.8	237
33	The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study. <i>Annals of Oncology</i> , 2001, 12, 633-641.	0.6	43
34	Pre- and Post-Radiotherapy Sexual Functioning in Prostate Cancer Patients. <i>Sexuality and Disability</i> , 2001, 19, 239-252.	0.4	10
35	A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 614-623.	0.4	128
36	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. <i>Prostate Journal</i> , 2001, 3, 30-35.	0.2	1
37	PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma. <i>Urologia Internationalis</i> , 2001, 66, 131-134.	0.6	1

#	ARTICLE	IF	CITATIONS
38	Contemporary measures for the assessment of health-related quality of life in prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 205-214.	0.7	1
39	Quality of life studies and genito-urinary tumors. <i>Annals of Oncology</i> , 2001, 12, S43-S48.	0.6	4
40	Statistical Methods for Quality of Life Studies. , 2002, , .		25
41	Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 557-566.	0.8	276
42	Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. <i>Urology</i> , 2002, 59, 394-398.	0.5	178
43	Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. <i>Urology</i> , 2002, 60, 12-18.	0.5	78
44	Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system. <i>Archives of Physical Medicine and Rehabilitation</i> , 2002, 83, S10-S17.	0.5	201
46	Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 557-566.	0.8	346
47	Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. <i>Current Urology Reports</i> , 2002, 3, 232-238.	1.0	2
48	Functional status and the elderly cancer patient. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 191-208.	2.0	46
49	The families evaluation on management, care and disclosure for terminal stage cancer patients. <i>BMC Palliative Care</i> , 2002, 1, 3.	0.8	29
50	American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 462-470.	0.4	58
51	Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. <i>Quality of Life Research</i> , 2002, 11, 207-221.	1.5	438
52	The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. <i>British Journal of Health Psychology</i> , 2003, 8, 125-134.	1.9	97
53	Quality of life after treatment for prostate cancer. <i>Current Prostate Reports</i> , 2003, 1, 55-65.	0.1	1
54	Quality of life after treatment for prostate cancer. <i>Current Urology Reports</i> , 2003, 4, 185-195.	1.0	61
55	Early Prostate Cancer: Prevention, Treatment Modalities, and Quality of Life Issues. <i>European Urology</i> , 2003, 44, 283-293.	0.9	28
56	An evidence-based approach to prostate cancer follow-up. <i>Seminars in Oncology</i> , 2003, 30, 390-400.	0.8	9

#	ARTICLE	IF	CITATIONS
57	Leading the Way in Exercise and Diet (Project LEAD):. Contemporary Clinical Trials, 2003, 24, 206-223.	2.0	78
58	The Memorial Anxiety Scale for Prostate Cancer. Cancer, 2003, 97, 2910-2918.	2.0	197
59	Health Related Quality of Life in Men With Prostate Cancer. Journal of Urology, 2003, 169, 1653-1661.	0.2	166
60	Clinical, Demographic and Psychosocial Correlates of Complementary and Alternative Medicine Use by Men Diagnosed With Localized Prostate Cancer. Journal of Urology, 2003, 170, 166-169.	0.2	56
61	The physical burden of prostate cancer. Urologic Clinics of North America, 2003, 30, 305-313.	0.8	34
62	Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health and Quality of Life Outcomes, 2003, 1, 69.	1.0	26
63	The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health and Quality of Life Outcomes, 2003, 1, 79.	1.0	1,119
64	Measuring self-reported sexual function in men with prostate cancer. Urology, 2003, 62, 596-606.	0.5	9
65	Health Outcomes Assessment in Cancer. Disease Management and Health Outcomes, 2003, 11, 709-721.	0.3	2
66	What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation, 2003, 21, 526-535.	0.6	94
67	Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial. Journal of Clinical Oncology, 2003, 21, 679-689.	0.8	360
68	Patient-Reported Toxicity Correlated to Doseâ€œVolume Histograms of the Rectum in Radiotherapy of the Prostate. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, e144-e149.	0.6	7
69	Measuring Patientsâ€™ Perceptions of the Outcomes of Treatment for Early Prostate Cancer. Medical Care, 2003, 41, 923-936.	1.1	117
70	Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Current Opinion in Urology, 2003, 13, 153-156.	0.9	21
71	Design of FRESH START: A Randomized Trial of Exercise and Diet among Cancer Survivors. Medicine and Science in Sports and Exercise, 2003, 35, 415-424.	0.2	68
72	Measuring quality of life in prostate cancer: progress and challenges. , 2004, , 126-159.		3
73	Evaluating quality of life in cancer survivors. , 2004, , 241-263.		6
74	Statistical issues in the application of cancer outcome measures. , 2004, , 362-385.		3

#	ARTICLE	IF	CITATIONS
75	Health-related quality of life after prostate brachytherapy. <i>BJU International</i> , 2004, 94, 487-491.	1.3	4
76	Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. <i>International Journal of Urology</i> , 2004, 11, 735-741.	0.5	60
77	Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy. <i>Patient Education and Counseling</i> , 2004, 55, 55-61.	1.0	38
78	Patient and Partner Quality of Life and Psychosocial Adjustment Following Radical Prostatectomy. <i>Journal of Clinical Psychology in Medical Settings</i> , 2004, 11, 15-30.	0.8	39
79	Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2004, 18, 879-897.	1.3	220
80	Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 34-42.	0.4	7
81	Interest in services among prostate cancer patients receiving androgen deprivation therapy. <i>Psycho-Oncology</i> , 2004, 13, 512-525.	1.0	28
82	Differences in health-related quality of life of prostate cancer patients based on stage of cancer. <i>Psycho-Oncology</i> , 2004, 13, 800-807.	1.0	58
83	Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma. <i>Cancer</i> , 2004, 101, 2202-2208.	2.0	33
84	The "Palliative Care Quality of Life Instrument (PQLI)" in terminal cancer patients. <i>Health and Quality of Life Outcomes</i> , 2004, 2, 8.	1.0	46
85	Management of Prostate Cancer. , 2004, , .		2
86	Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1502-1512.	13.9	5,142
87	Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. <i>Urology</i> , 2004, 63, 273-277.	0.5	53
89	Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 956-964.	0.4	55
91	Prostate Cancer in the Elderly. <i>International Urology and Nephrology</i> , 2005, 37, 797-806.	0.6	7
92	Reliability and validity of the Functional Assessment of Cancer Therapy General (FACT-G) in French cancer patients. <i>Quality of Life Research</i> , 2005, 14, 1427-1432.	1.5	36
93	Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. <i>Prostate</i> , 2005, 63, 1-12.	1.2	58
95	Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. <i>Journal of Rehabilitation Research and Development</i> , 2005, 42, 391.	1.6	42

#	ARTICLE	IF	CITATIONS
96	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. <i>Future Oncology</i> , 2005, 1, 19-22.	1.1	13
97	Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 455-460.	0.8	195
98	Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2789-2796.	0.8	32
99	Data Pooling and Analysis to Build a Preliminary Item Bank. <i>Evaluation and the Health Professions</i> , 2005, 28, 142-159.	0.9	3
100	The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. <i>Annals of Oncology</i> , 2005, 16, 579-584.	0.6	301
101	Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 466-474.	2.4	41
102	Quality of life in prostate cancer. <i>European Journal of Cancer</i> , 2005, 41, 922-931.	1.3	22
103	Developing a Self-Report Outcome Measure for Complementary and Alternative Medicine. <i>Explore: the Journal of Science and Healing</i> , 2005, 1, 177-185.	0.4	12
104	Quality of life in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 208-215.	0.8	20
105	A Measure of Health-Related Quality of Life Among Patients with Localized Prostate Cancer: Results from Ongoing Scale Development. <i>Clinical Prostate Cancer</i> , 2005, 4, 100-108.	2.1	31
106	Assessing Anxiety in Men With Prostate Cancer: Further Data on the Reliability and Validity of the Memorial Anxiety Scale for Prostate Cancer (MAX <sup>®</sup> PC). <i>Psychosomatics</i> , 2006, 47, 340-347.	2.5	123
107	Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. <i>Radiotherapy and Oncology</i> , 2006, 81, 57-64.	0.3	100
108	Considerations of Cost-Effectiveness for New Radiation Oncology Technologies. <i>Journal of the American College of Radiology</i> , 2006, 3, 278-288.	0.9	6
109	Quality-of-Life Outcomes in Oncology. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 165-185.	0.9	25
110	Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?. <i>Urology</i> , 2006, 68, 599-603.	0.5	21
111	The Functional Assessment of Cancer Therapy-Prostate (FACT-P) Scales in Men with Prostate Cancer: Reliability and Validity of the Korean Version. <i>Journal of Korean Medical Science</i> , 2006, 21, 295.	1.1	20
112	Religion and spirituality among patients with localized prostate cancer. <i>Palliative and Supportive Care</i> , 2006, 4, 345-355.	0.6	18
113	Reclaiming Wellness-Living With Bodily Problems, As Narrated by Men With Advanced Prostate Cancer. <i>Cancer Nursing</i> , 2006, 29, 327-337.	0.7	39

#	ARTICLE	IF	CITATIONS
114	Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone-Refractory Prostate Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2006, 12, 299-304.	1.0	11
115	Patient and Physician Reporting of Symptoms and Health-related Quality of Life in Trials of Treatment for Early Prostate Cancer: Considerations for Future Studies. <i>Clinical Oncology</i> , 2006, 18, 735-743.	0.6	16
116	Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. <i>Quality of Life Research</i> , 2006, 15, 1297-1306.	1.5	60
117	Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasetan Influence Quality of Life?. <i>European Urology</i> , 2006, 49, 781-789.	0.9	21
118	Outcomes Research: A Methodologic Review. <i>European Urology</i> , 2006, 50, 218-224.	0.9	19
119	Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone. <i>Journal of Clinical Oncology</i> , 2006, 24, 2828-2835.	0.8	80
120	Lifestyle Intervention Development Study to Improve Physical Function in Older Adults With Cancer: Outcomes From Project LEAD. <i>Journal of Clinical Oncology</i> , 2006, 24, 3465-3473.	0.8	213
122	Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 4171-4177.	0.8	188
123	Prostate Cancer: A Chronic Illness. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 857-861.	0.3	8
124	Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. <i>Annals of Oncology</i> , 2007, 18, 1064-1070.	0.6	49
125	Handbook of Cancer Survivorship. , 2007, , .		43
126	Main Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print Intervention Among Breast and Prostate Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2709-2718.	0.8	260
127	Handbook of Urologic Cryoablation. , 2007, , .		3
128	Impact of Lower Urinary Tract Symptoms on Quality of Life Using Functional Assessment Cancer Therapy Scale. <i>Urology</i> , 2007, 69, 285-288.	0.5	31
129	Cryoablation as Primary Treatment for Localized Prostate Cancer Followed by Penile Rehabilitation. <i>Urology</i> , 2007, 69, 306-310.	0.5	65
130	Exercise Prevents Fatigue and Improves Quality of Life in Prostate Cancer Patients Undergoing Radiotherapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2007, 88, 1416-1422.	0.5	146
131	Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. <i>Contemporary Clinical Trials</i> , 2007, 28, 763-769.	0.8	67
132	The effects of prostate cancer on intimate relationships. <i>The Journal of Men's Health &amp; Gender: the Official Journal of the International Society for Men's Health &amp; Gender</i> , 2007, 4, 226-232.	0.3	9



#	ARTICLE	IF	CITATIONS
133	The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN4772397). <i>Radiotherapy and Oncology</i> , 2007, 83, 31-41.	0.3	63
134	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. <i>Lancet Oncology</i> , The, 2007, 8, 475-487.	5.1	843
136	Analysis Linking UCLA PCI With Expanded Prostate Cancer Index Composite: An Evaluation of Health Related Quality of Life in Japanese Men With Localized Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 473-477.	0.2	24
137	Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 34.	1.0	39
138	Depression and quality of life in cancer survivors: is there a relationship with physical activity?. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2007, 4, 65.	2.0	27
139	Impact of providing audiotapes of primary treatment consultations to men with prostate cancer: a multi-site, randomized, controlled trial. <i>Psycho-Oncology</i> , 2007, 16, 543-552.	1.0	61
140	Extending the validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at the time of prostate biopsy in a racially-mixed population. <i>Psycho-Oncology</i> , 2007, 16, 493-498.	1.0	20
141	The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 4772397). <i>BJU International</i> , 2007, 99, 301-310.	1.3	26
142	A phase II trial of gefitinib in patients with nonâ€metastatic hormoneâ€refractory prostate cancer. <i>BJU International</i> , 2007, 100, 765-769.	1.3	61
143	Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients. <i>Value in Health</i> , 2007, 10, 408-414.	0.1	73
144	ORIGINAL RESEARCHâ€”ERECTILE DYSFUNCTION: Determinants of Sexual Satisfaction in Men with Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2007, 4, 1422-1427.	0.3	60
145	Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 53-61.	1.1	4
146	Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. <i>Quality of Life Research</i> , 2007, 16, 571-575.	1.5	60
147	Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. <i>Quality of Life Research</i> , 2007, 16, 1665-1675.	1.5	9
148	Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 869-876.	1.0	130
150	Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization. <i>Quality of Life Research</i> , 2008, 17, 1137-1146.	1.5	109
151	Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1385-1396.	1.2	24
152	Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT). <i>Radiation Oncology</i> , 2008, 3, 20.	1.2	10

#	ARTICLE	IF	CITATIONS
153	Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 353-360.	0.4	61
154	Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 421-432.	0.4	152
155	Quality of Life in Men Treated With Carbon Ion Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1010-1015.	0.4	20
156	Management of Complications of Prostate Cancer Treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 196-213.	157.7	156
157	Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2008, 18, 67-72.	1.0	34
158	Endothelin-1-induced pain and hyperalgesia: A review of pathophysiology, clinical manifestations and future therapeutic options. <i>Neuropeptides</i> , 2008, 42, 119-132.	0.9	62
160	Does "Normal" Aging Imply Urinary, Bowel, and Erectile Dysfunction? A General Population Survey. <i>Urology</i> , 2008, 72, 3-9.	0.5	58
161	Prostate Cancer: Epidemiology and Health-related Quality of Life. <i>Urology</i> , 2008, 72, S3-S11.	0.5	29
162	An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. <i>European Journal of Cancer</i> , 2008, 44, 2418-2424.	1.3	370
163	Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. <i>European Journal of Oncology Nursing</i> , 2008, 12, 283-290.	0.9	27
165	Measuring the individual quality of life of patients with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2008, 11, 390-396.	2.0	17
166	Quality of Life of Men with Biochemical Recurrence of Prostate Cancer. <i>Journal of Psychosocial Oncology</i> , 2008, 26, 17-34.	0.6	25
167	Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 242-245.	0.8	987
168	Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. <i>Annals of Oncology</i> , 2008, 19, 1749-1753.	0.6	98
169	Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: The moderating role of age. <i>Psychology, Health and Medicine</i> , 2008, 13, 146-161.	1.3	23
170	Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study. <i>Clinical Cancer Research</i> , 2008, 14, 2763-2767.	3.2	179
171	Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists?. <i>Journal of the Royal Society of Medicine</i> , 2008, 101, 133-138.	1.1	29
172	Perspective on "Chemotherapy for Advanced Prostate Cancer: 25 Years Later" Is It a Mirage or an Oasis?. <i>Journal of Clinical Oncology</i> , 2008, 26, 4049-4050.	0.8	2

#	ARTICLE	IF	CITATIONS
173	Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 188-194.	0.6	2
174	Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. <i>Urologia Internationalis</i> , 2009, 82, 196-202.	0.6	5
175	The Chronology of Distress, Anxiety, and Depression in Older Prostate Cancer Patients. <i>Oncologist</i> , 2009, 14, 891-899.	1.9	86
177	Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 333-338.	2.0	70
178	Quality of life in patients with prostate cancer: development and application of a hybrid assessment method. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 72-77.	2.0	2
179	Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. <i>Journal of Clinical Oncology</i> , 2009, 27, 2015-2021.	0.8	69
180	The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 160-164.	1.2	16
181	The Role of Spirituality in the Relationship Between Religiosity and Depression in Prostate Cancer Patients. <i>Annals of Behavioral Medicine</i> , 2009, 38, 105-114.	1.7	95
182	Cancer-related pain and quality of life in prostate cancer patients: Assessment using the Functional Assessment of Prostate Cancer Therapy. <i>International Journal of Urology</i> , 2009, 16, 522-525.	0.5	16
183	Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. <i>International Journal of Urology</i> , 2009, 16, 726-731.	0.5	9
184	Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. <i>International Journal of Urology</i> , 2009, 16, 731-732.	0.5	0
185	Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy-Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer. <i>Value in Health</i> , 2009, 12, 124-129.	0.1	163
186	Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer. <i>Urology</i> , 2009, 73, 635-640.	0.5	17
188	Comparing Eccentric Resistance Exercise in Prostate Cancer Survivors On and Off Hormone Therapy: A Pilot Study. <i>PM and R</i> , 2009, 1, 1019-1024.	0.9	46
190	Prospective Study of Outcomes after Percutaneous Biliary Drainage for Malignant Biliary Obstruction. <i>Annals of Surgical Oncology</i> , 2010, 17, 2303-2311.	0.7	77
191	Cuestionario Español de Calidad de Vida en Pacientes con Cáncer de Próstata como medida de la calidad de vida de los pacientes con cáncer de próstata en España: aplicación a la actividad diaria. <i>Actas Urológicas Españolas</i> , 2010, 34, 686-693.	0.3	9
192	Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 773-783.	0.4	77
193	Validation of the Intestinal Part of the Prostate Cancer Questionnaire - QLQFW94 - Psychometric Properties, Responsiveness, and Content Validity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 793-804.	0.4	9

#	ARTICLE	IF	CITATIONS
194	A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy. <i>Trials</i> , 2010, 11, 86.	0.7	16
195	Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. <i>Psycho-Oncology</i> , 2010, 19, 606-616.	1.0	76
196	Distress, anxiety, depression, and emotional well-being in African-American men with prostate cancer. <i>Psycho-Oncology</i> , 2010, 19, 1052-1060.	1.0	34
197	Health-related quality of life in men with localized prostate cancer. <i>International Journal of Urology</i> , 2010, 17, 125-138.	0.5	50
198	Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: A prospective study. <i>International Journal of Urology</i> , 2010, 17, 715-719.	0.5	57
199	Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. <i>Patient Related Outcome Measures</i> , 2010, 1, 119.	0.7	45
200	Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens. <i>Journal of Clinical Oncology</i> , 2010, 28, 5054-5060.	0.8	23
201	CAVIPRES questionnaire as a measurement of quality of life in patients with prostate cancer in Spain: Daily clinical practice application. <i>Actas Urológicas Españolas (English Edition)</i> , 2010, 34, 686-693.	0.2	4
202	Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 270-281.	2.4	46
204	Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors. <i>Urology</i> , 2010, 76, 1245-1250.	0.5	356
205	Comparison of Validated Instruments Measuring Sexual Function in Men. <i>Urology</i> , 2010, 76, 380-386.	0.5	18
206	Quality-of-life concerns in lung cancer patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 667-676.	0.7	8
207	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736
208	Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial. <i>Journal of Urology</i> , 2011, 185, 1246-1255.	0.2	223
209	Living with Bodily Changes in Hormone-Refractory Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2011, 27, 309-316.	0.7	4
210	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. <i>Lancet, The</i> , 2011, 378, 2104-2111.	6.3	522
211	Quality of Life of Patients with Hormone Refractory Prostate Cancer After Gene Therapy. , 0, , .		0
213	Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. <i>Cancer Biomarkers</i> , 2011, 8, 81-87.	0.8	13

#	ARTICLE	IF	CITATIONS
214	The Association Between Erectile Dysfunction and Depressive Symptoms in Men Treated for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2011, 8, 560-566.	0.3	95
215	Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach. <i>Quality of Life Research</i> , 2011, 20, 371-381.	1.5	70
216	Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 99-113.	1.2	10
217	Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?. <i>Medical Oncology</i> , 2011, 28, 519-527.	1.2	11
218	Exercise Interventions for Cancer Survivors: A Meta-Analysis of Quality of Life Outcomes. <i>Annals of Behavioral Medicine</i> , 2011, 41, 32-47.	1.7	230
219	Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men. <i>Reproductive Medicine and Biology</i> , 2011, 10, 59-68.	1.0	6
220	Racial differences in well-being and cancer concerns in prostate cancer patients. <i>Journal of Cancer Survivorship</i> , 2011, 5, 182-190.	1.5	12
221	A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. <i>Psycho-Oncology</i> , 2011, 20, 435-440.	1.0	17
222	Developing a Valid Patient-Reported Outcome Measure. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 737-742.	2.3	144
223	Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 647-657.	1.1	136
224	Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature. <i>Cancer Investigation</i> , 2012, 30, 1-12.	0.6	22
225	The Role of Signs or Symptoms. , 2012, , 121-158.		0
226	Design and Analysis of Quality-of-Life Data. , 2012, , 339-368.		2
227	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 1187-1197.	13.9	3,847
228	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. <i>Lancet Oncology</i> , The, 2012, 13, 622-632.	5.1	359
229	Quality of Life with Advanced Metastatic Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 505-515.	0.8	23
232	A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy. <i>BMC Cancer</i> , 2012, 12, 103.	1.1	10
233	Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy. <i>BMC Cancer</i> , 2012, 12, 324.	1.1	17

#	ARTICLE	IF	CITATIONS
234	Effects of androgen deprivation on brain function in prostate cancer patients – a prospective observational cohort analysis. <i>BMC Cancer</i> , 2012, 12, 371.	1.1	60
235	Validation in Spain of the Quality of Life questionnaire PROSQOLI in patients with advanced prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 410-417.	0.2	1
236	Re: Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: A Prospective Development Study. <i>Journal of Urology</i> , 2012, 188, 1768-1769.	0.2	2
237	Quality of Life of Patients with Ovarian Cancer. , 0, , .		0
238	Study of dyadic communication in couples managing prostate cancer: a longitudinal perspective. <i>Psycho-Oncology</i> , 2012, 21, 72-81.	1.0	59
239	Fear of cancer recurrence: a systematic literature review of self-report measures. <i>Psycho-Oncology</i> , 2012, 21, 571-587.	1.0	196
240	Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy. <i>Cancer</i> , 2012, 118, 4139-4147.	2.0	18
241	Body image predicts quality of life in men with prostate cancer. <i>Psycho-Oncology</i> , 2013, 22, 756-761.	1.0	36
242	Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials. <i>Quality of Life Research</i> , 2013, 22, 2777-2786.	1.5	10
243	A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. <i>Quality of Life Research</i> , 2013, 22, 2951-2962.	1.5	22
244	The impact of clinical and sociodemographic features on quality of life in patients with early stage cancers using the Functional Assessment of Cancer Therapy-General assessment tool. <i>Supportive Care in Cancer</i> , 2013, 21, 2267-2277.	1.0	5
245	Randomized Controlled Trial of a Behavior Change Intervention to Increase Physical Activity and Quality of Life in Prostate Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2013, 46, 382-393.	1.7	34
246	Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review. <i>Value in Health</i> , 2013, 16, 872-890.	0.1	15
247	2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 117-124.	5.1	195
248	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 760-768.	5.1	256
249	Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 352-358.	0.8	56
250	Quality of life in men receiving radiotherapy and neoadjuvant androgen deprivation for prostate cancer: results from a prospective longitudinal study. <i>Journal of Advanced Nursing</i> , 2013, 69, 53-65.	1.5	20
251	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. <i>European Journal of Cancer</i> , 2013, 49, 3648-3657.	1.3	77



#	ARTICLE	IF	CITATIONS
252	Urinary function and health-related quality of life of patients after laparoscopic radical prostatectomy: two methods of assessment for 112 patients with up to six years of follow-up. <i>Journal of Clinical Urology</i> , 2013, 6, 32-44.	0.1	0
253	A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human $\alpha\text{V}\beta_3$ integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 329-336.	0.6	69
254	Examining a Therapeutic Yoga Program for Prostate Cancer Survivors. <i>Integrative Cancer Therapies</i> , 2013, 12, 113-125.	0.8	23
255	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. <i>BJU International</i> , 2013, 111, E158-66.	1.3	61
256	A randomized controlled trial of a self-management psychosocial intervention for men with prostate cancer and their partners: a study protocol. <i>Journal of Advanced Nursing</i> , 2013, 69, 2572-2583.	1.5	21
257	Cancer-Specific Concerns and Physical Activity Among Recently Diagnosed Breast and Prostate Cancer Survivors. <i>Integrative Cancer Therapies</i> , 2013, 12, 206-212.	0.8	27
258	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. <i>Psycho-Oncology</i> , 2013, 22, 2169-2176.	1.0	36
259	Factors associated with adherence to physical activity guidelines in patients with prostate cancer. <i>Psycho-Oncology</i> , 2013, 22, 2478-2486.	1.0	44
260	Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4092-4098.	0.8	38
261	Safety and activity of sunitinib in elderly patients ( $\geq 70$ years) with metastatic renal cell carcinoma: a multicenter study. <i>Annals of Oncology</i> , 2013, 24, 336-342.	0.6	42
262	Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 111-122.	2.0	41
263	Cancer Patient and Survivor Research From the Cancer Information Service Research Consortium: A Preview of Three Large Randomized Trials and Initial Lessons Learned. <i>Journal of Health Communication</i> , 2013, 18, 543-562.	1.2	29
264	A Randomized Trial of Aerobic versus Resistance Exercise in Prostate Cancer Survivors. <i>Journal of Aging and Physical Activity</i> , 2013, 21, 455-478.	0.5	61
265	Evidence from clinical trials for the use of valproic acid in solid tumors: focus on prostate cancer. <i>Clinical Investigation</i> , 2013, 3, 467-478.	0.0	6
266	Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer. <i>Prostate International</i> , 2013, 1, 117-124.	1.2	6
267	Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 105.	0.3	13
268	Community-Based Recreational Football: A Novel Approach to Promote Physical Activity and Quality of Life in Prostate Cancer Survivors. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 5567-5585.	1.2	31
270	Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 523-531.	0.6	14

#	ARTICLE	IF	CITATIONS
271	Calidad de vida en pacientes con cncer de prstata, operados de prostatectoma radical laparoscpica. Revista Mexicana De Urologia, 2014, 74, 133-140.	0.0	4
272	Anxiety in the management of localised prostate cancer by active surveillance. BJU International, 2014, 114, 55-61.	1.3	54
273	Relationship between sexual function and prostatespecific antigen bounce after iodine125 permanent implant brachytherapy for localized prostate cancer. International Journal of Urology, 2014, 21, 658-663.	0.5	3
274	Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. BMC Surgery, 2014, 14, 89.	0.6	40
275	Comparison of Health-related Quality of Life Between Cancer Survivors Treated in Designated Cancer Centers and the General Public in Korea. Japanese Journal of Clinical Oncology, 2014, 44, 141-152.	0.6	16
276	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer, 2014, 12, 41-49.	0.9	31
277	Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 26.e25-26.e31.	0.8	2
278	Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial. European Urology, 2014, 65, 865-872.	0.9	164
279	Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. Cancer Treatment Reviews, 2014, 40, 170-177.	3.4	39
280	Concept and viability of androgen annihilation for advanced prostate cancer. Cancer, 2014, 120, 2628-2637.	2.0	16
281	Healthrelated quality of life after carbonion radiotherapy for prostate cancer: A 3year prospective study. International Journal of Urology, 2014, 21, 370-375.	0.5	8
282	Quality-of-life assessment tools for men with prostate cancer. Nature Reviews Urology, 2014, 11, 352-359.	1.9	11
283	Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials. Journal of the National Cancer Institute, 2014, 106, .	3.0	83
284	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
285	A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemporary Clinical Trials, 2014, 39, 57-65.	0.8	53
286	Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health and Quality of Life Outcomes, 2014, 12, 104.	1.0	26
287	The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial. Trials, 2014, 15, 354.	0.7	14
288	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs, 2014, 32, 1005-1016.	1.2	29



#	ARTICLE	IF	CITATIONS
289	Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. <i>Quality of Life Research</i> , 2014, 23, 2169-2181.	1.5	56
290	Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases. <i>Drugs</i> , 2014, 74, 579-586.	4.9	34
291	Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. <i>Journal of Geriatric Oncology</i> , 2014, 5, 119-126.	0.5	68
292	Educational Needs for Sexual Health and Its Effect on Depression and the Quality of Life in Patients with Prostate Cancer. <i>Asian Oncology Nursing</i> , 2015, 15, 163.	0.2	6
293	Effect of Qianlie Xiaozheng Tang, a Chinese herbal decoction, on castration resistant prostate cancer: A pilot study. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2015, 12, 21.	0.3	3
294	Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2151-2157.	0.8	39
295	A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 312.	1.1	22
296	Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e385-e386.	0.9	5
298	How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. <i>European Urology</i> , 2015, 67, 637-645.	0.9	105
299	Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor. <i>Cancer Treatment Reviews</i> , 2015, 41, 247-253.	3.4	4
300	Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. <i>World Journal of Urology</i> , 2015, 33, 1503-1509.	1.2	108
301	Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. <i>Quality of Life Research</i> , 2015, 24, 591-598.	1.5	22
303	Improving Couples™ Quality of Life Through a Web-Based Prostate Cancer Education Intervention. <i>Oncology Nursing Forum</i> , 2015, 42, 183-192.	0.5	60
304	Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 281-287.	2.0	20
305	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 509-521.	5.1	174
306	Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer. <i>Quality of Life Research</i> , 2015, 24, 2397-2402.	1.5	11
307	Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. <i>Annals of Oncology</i> , 2015, 26, 179-185.	0.6	66
308	A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. <i>BMC Urology</i> , 2015, 15, 94.	0.6	28

#	ARTICLE	IF	CITATIONS
309	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2015, 16, 1605-1616.	5.1	126
310	Health-related quality of life in men with metastatic castration-resistant prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 941-949.	0.7	3
311	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer going beyond PSA and imaging, a systematic literature review. <i>Annals of Oncology</i> , 2015, 26, 2221-2247.	0.6	10
312	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. <i>European Urology</i> , 2015, 68, 927-936.	0.9	163
313	Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e19-69.e28.	0.8	58
314	Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy. <i>Cancer Nursing</i> , 2016, 39, 3-11.	0.7	14
315	Oncology Section EDGE Task Force on Prostate Cancer. <i>Rehabilitation Oncology</i> , 2016, 34, 27-35.	0.2	10
316	Quality of Life: Impact of Prostate Cancer and its Treatment. , 2016, , 579-584.		2
317	Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Research and Reports in Urology</i> , 2016, Volume 8, 217-224.	0.6	4
318	The role of mindfulness in distress and quality of life for men with advanced prostate cancer. <i>Quality of Life Research</i> , 2016, 25, 3027-3035.	1.5	24
319	Patient-reported outcomes in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 643-650.	12.5	27
320	USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002-2015. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 97-106.	0.2	10
321	Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. <i>World Journal of Urology</i> , 2016, 34, 1373-1382.	1.2	62
322	Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men. <i>Journal of Sexual Medicine</i> , 2016, 13, 425-434.	0.3	104
323	Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate) <i>Tj ETQq0 0 0 rgBI /Overlock 10 Tf 50</i>		
324	Symptomatic and quality of life outcomes after treatment for clinically localised prostate cancer: a systematic review. <i>BJU International</i> , 2016, 118, 193-204.	1.3	63
325	Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). <i>Prostate</i> , 2016, 76, 1519-1527.	1.2	16
326	Patient-reported outcome measures in metastatic prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2016, 7, 28-32.	0.2	9

#	ARTICLE	IF	CITATIONS
327	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. <i>Future Oncology</i> , 2016, 12, 2689-2699.	1.1	5
328	Psychosocial screening for patients with prostate cancer: The development and validation of the psychosocial distress questionnaire-prostate cancer. <i>Journal of Psychosocial Oncology</i> , 2016, 34, 512-529.	0.6	1
329	Therapy Update for Metastatic Castration-Resistant Prostate Cancer. <i>The Consultant Pharmacist</i> , 2016, 31, 581-592.	0.4	0
330	“What if?” Decisional Regret in Patients who Discontinued Active Surveillance. <i>Tumori</i> , 2016, 102, 562-568.	0.6	6
331	Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 168.	1.0	9
332	The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. <i>Quality of Life Research</i> , 2016, 25, 2379-2393.	1.5	14
333	Relationship of Mitochondrial Enzymes to Fatigue Intensity in Men With Prostate Cancer Receiving External Beam Radiation Therapy. <i>Biological Research for Nursing</i> , 2016, 18, 274-280.	1.0	14
334	Health-related quality of life of Chinese patients with prostate cancer in comparison to general population and other cancer populations. <i>Supportive Care in Cancer</i> , 2016, 24, 1849-1856.	1.0	15
335	Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 1046-1054.	0.6	5
336	Higher-intensity exercise helps cancer survivors remain motivated. <i>Journal of Cancer Survivorship</i> , 2016, 10, 524-533.	1.5	6
337	Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 111-121.	2.0	58
338	Leveraging Outcomes Research to Optimize Prostate Cancer Care. <i>Urology Practice</i> , 2016, 3, 25-31.	0.2	0
339	Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. <i>Annals of Oncology</i> , 2016, 27, 868-874.	0.6	145
340	Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data. <i>European Journal of Health Economics</i> , 2017, 18, 181-193.	1.4	4
341	Threat of Sexual Disqualification: The Consequences of Erectile Dysfunction and Other Sexual Changes for Gay and Bisexual Men With Prostate Cancer. <i>Archives of Sexual Behavior</i> , 2017, 46, 2043-2057.	1.2	63
342	The Role of a Standardized Clinical Care Pathway in Patient Satisfaction and Quality of Life Outcomes after Robotic Assisted Laparoscopic Radical Prostatectomy. <i>Urology Practice</i> , 2017, 4, 232-238.	0.2	0
343	Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 110-116.	2.0	43
344	The influence of stigma on the quality of life for prostate cancer survivors. <i>Journal of Psychosocial Oncology</i> , 2017, 35, 451-467.	0.6	14

#	ARTICLE	IF	CITATIONS
345	Patient-reported outcome (<scp>PRO</scp>) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments. <i>BJU International</i> , 2017, 120, 468-481.	1.3	29
346	Patient-reported outcome measures in urology. <i>Current Opinion in Urology</i> , 2017, 27, 366-374.	0.9	29
347	Patient-reported outcomes in cancer survivorship. <i>Acta Oncológica</i> , 2017, 56, 166-173.	0.8	39
348	Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings. <i>Patient</i> , 2017, 10, 567-578.	1.1	17
349	The Relationships Between Spiritual Well-Being, Quality of Life, and Psychological Factors Before Radiotherapy for Prostate Cancer. <i>Journal of Religion and Health</i> , 2017, 56, 1846-1855.	0.8	9
350	Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 291-297.	0.8	69
351	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. <i>European Journal of Cancer</i> , 2017, 87, 21-29.	1.3	26
352	Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy. <i>European Journal of Oncology Nursing</i> , 2017, 30, 84-90.	0.9	16
353	Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer. <i>Cancer Nursing</i> , 2017, 40, 412-419.	0.7	30
354	A Model of Consultation in Prostate Cancer Care. <i>Cancer Nursing</i> , 2017, 40, 276-288.	0.7	20
355	Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2017, 2, 5-12.	0.6	4
356	Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Current Urology</i> , 2017, 10, 169-173.	0.4	12
357	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 130.	1.0	27
358	Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. <i>Quality of Life Research</i> , 2017, 26, 813-822.	1.5	14
359	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017, 71, 534-542.	0.9	28
360	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	0.9	11
361	High Levels of Medical Mistrust are Associated with Low Quality of Life among Black and White Men with Prostate Cancer. <i>Cancer Control</i> , 2017, 24, 72-77.	0.7	51
362	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 456.	0.7	6

#	ARTICLE	IF	CITATIONS
363	Dose-escalated radiotherapy for clinically localised and locally advanced prostate cancer. The Cochrane Library, 0, , .	1.5	2
364	Development and Initial Validation of the Novel Scale for Assessing Quality of Life of Prostate Cancer Patients Receiving Androgen Deprivation Therapy. Chinese Medical Journal, 2017, 130, 2082-2087.	0.9	1
365	Symptoms predicting health-related quality of life in prostate cancer patients treated with localized radiation therapy. Family Medicine and Community Health, 2017, 5, 119-128.	0.6	2
366	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Cancer Management and Research, 2017, Volume 9, 299-306.	0.9	3
367	Basic methods for the assessment of health-related quality of life in uro-oncological patients. Minerva Urology and Nephrology, 2017, 69, 409-420.	1.3	6
368	Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. Trials, 2017, 18, 451.	0.7	17
369	Preliminary experience with dosimetry, response and patient reported outcome after <sup>177</sup> Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget, 2017, 8, 3581-3590.	0.8	172
370	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncology, 2018, 14, 527-536.	1.1	0
371	Castrate-resistant prostate cancer: lessons learnt from a pilot study in the palliative care research population. International Journal of Palliative Nursing, 2018, 24, 96-98.	0.2	0
372	Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab). European Journal of Cancer, 2018, 97, 33-40.	1.3	10
373	Perceptions of masculinity and body image in men with prostate cancer: the role of exercise. Supportive Care in Cancer, 2018, 26, 3379-3388.	1.0	28
374	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. European Urology, 2018, 73, 870-876.	0.9	44
375	Evaluating a psychosocial intervention for men with prostate cancer and their partners: Outcomes and lessons learned from a randomized controlled trial. Applied Nursing Research, 2018, 40, 143-151.	1.0	22
376	Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Supportive Care in Cancer, 2018, 26, 1917-1926.	1.0	34
377	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 194-206.	5.1	126
378	Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer, 2018, 18, 368.	1.1	73
379	Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology, 2018, 178, 565-576.	1.9	13
380	Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 10-15.	0.7	6

#	ARTICLE	IF	CITATIONS
381	The Effect on Bone Outcomes of Home-based Exercise Intervention for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. <i>Cancer Nursing</i> , 2018, 41, 379-388.	0.7	25
382	Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e151-e159.	0.9	4
383	Health-Related Quality of Life and Urolithiasis. , 2018, , 17-27.		3
384	eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 149-154.	0.9	26
385	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1088-1095.	0.8	72
386	Quality of life in active surveillance and the associations with decision-making—a literature review. <i>Translational Andrology and Urology</i> , 2018, 7, 160-169.	0.6	8
387	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 27.	0.9	10
388	Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>Advances in Therapy</i> , 2018, 35, 2186-2200.	1.3	7
389	Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. <i>BMC Cancer</i> , 2018, 18, 1031.	1.1	3
390	Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. <i>American Journal of Men's Health</i> , 2018, 12, 1807-1823.	0.7	303
391	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1404-1416.	5.1	105
392	RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2018, 15, 49.	2.0	52
393	Cancer symptom response as an oncology clinical trial end point. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018, 3, 35-46.	0.6	10
394	Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 364.e15-364.e22.	0.8	11
395	An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (<scp>CAPRISTANA</scp>). <i>BJU International</i> , 2019, 123, 456-464.	1.3	15
396	Ambulatory Robot-Assisted Laparoscopic Prostatectomy: Is It Ready for Prime Time? A Quality of Life Analysis. <i>Journal of Endourology</i> , 2019, 33, 814-822.	1.1	17
397	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530.	5.1	69
398	PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study. <i>BMC Urology</i> , 2019, 19, 92.	0.6	20



#	ARTICLE	IF	CITATIONS
399	Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). <i>Pilot and Feasibility Studies</i> , 2019, 5, 102.	0.5	8
400	Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. <i>European Urology</i> , 2019, 76, 823-830.	0.9	21
401	Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 1099-1105.	0.5	2
402	Quality of Life—“Focused Decision-Making for Prostate Cancer. <i>Current Urology Reports</i> , 2019, 20, 57.	1.0	15
403	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002936.	3.9	30
404	Improving quality of life among latino cancer survivors: Design of a randomized trial of patient navigation. <i>Contemporary Clinical Trials</i> , 2019, 76, 41-48.	0.8	7
405	Meaningful differences and validity for the NCCN/FACT—P Symptom Index: An analysis of the ALSYMPCA data. <i>Cancer</i> , 2019, 125, 1877-1885.	2.0	4
406	Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life. <i>Prostate International</i> , 2019, 7, 108-113.	1.2	11
407	A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2019, 19, 2.	1.1	34
408	Investigating the role of psychological flexibility, masculine self-esteem and stoicism as predictors of psychological distress and quality of life in men living with prostate cancer. <i>European Journal of Cancer Care</i> , 2019, 28, e13097.	0.7	26
409	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24.	13.9	904
410	The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. <i>BMC Cancer</i> , 2019, 19, 487.	1.1	8
411	Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1202-1211.	1.1	34
412	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	1.9	32
413	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	5.1	90
414	Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results. <i>BMJ Open</i> , 2019, 9, e031904.	0.8	9
415	Hypofractionation for clinically localized prostate cancer. <i>The Cochrane Library</i> , 2019, 2019, CD011462.	1.5	28
416	Unmet supportive care needs in Hispanic/Latino cancer survivors: prevalence and associations with patient-provider communication, satisfaction with cancer care, and symptom burden. <i>Supportive Care in Cancer</i> , 2019, 27, 1383-1394.	1.0	46

#	ARTICLE	IF	CITATIONS
417	A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. <i>Journal of Bone Oncology</i> , 2019, 14, 100212.	1.0	24
418	Investigating the relationships between quality of life, fatigue and leisure time physical activity in prostate cancer patients. <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 2019, 32, 497-503.	0.4	5
419	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. <i>European Urology</i> , 2019, 75, 940-947.	0.9	60
420	Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. <i>Clinical Oncology</i> , 2019, 31, 99-107.	0.6	12
421	Prostate cancer: the influence of stigma on quality of life and relationship satisfaction for survivors and their partners. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 350-366.	0.6	11
422	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. <i>Sports Medicine</i> , 2019, 49, 145-158.	3.1	33
423	Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. <i>International Journal of Radiation Biology</i> , 2020, 96, 324-339.	1.0	35
424	Patient-reported Outcome Measures in Metastatic Urinary Cancers. <i>European Urology Focus</i> , 2020, 6, 26-30.	1.6	11
425	Development of the Functional Assessment of Cancer Therapyâ€“Immune Checkpoint Modulator (FACTâ€“ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26
426	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.	0.4	42
427	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	0.8	24
428	Assessing the effect of patient navigator assistance for psychosocial support services on healthâ€“related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors. <i>Cancer</i> , 2020, 126, 1112-1123.	2.0	19
429	Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 512-526.	1.3	17
430	Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?. <i>International Journal of Impotence Research</i> , 2020, 32, 495-502.	1.0	8
431	Focal Salvage MR Imagingâ€“Guided Cryoablation for Localized Prostate Cancer Recurrence after Radiotherapy: 12-Month Follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 35-41.	0.2	22
432	United in Fight against prostate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. <i>BJU International</i> , 2020, 125, 541-552.	1.3	12
433	Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial. <i>Clinical Rehabilitation</i> , 2020, 34, 320-333.	1.0	14
434	Religious Coping and Quality of Life Among Black and White Men With Prostate Cancer. <i>Cancer Control</i> , 2020, 27, 107327482093628.	0.7	11



#	ARTICLE	IF	CITATIONS
435	Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 369-378.	0.3	0
436	Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial. <i>BMJ Open</i> , 2020, 10, e038678.	0.8	1
437	A systematic review of tools used to assess body image, masculinity and self-esteem in men with prostate cancer. <i>Psycho-Oncology</i> , 2020, 29, 1761-1771.	1.0	6
438	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2020, 12, 2568.	1.7	8
439	Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. <i>Cancers</i> , 2020, 12, 2550.	1.7	7
440	Quality of life, depression, and psychosocial mechanisms of suicide risk in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E487-E492.	0.3	4
441	Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer – 5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. <i>Clinical Oncology</i> , 2020, 32, e177-e187.	0.6	11
442	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	1.6	19
443	Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers. <i>Current Oncology Reports</i> , 2020, 22, 21.	1.8	5
444	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020, 78, 603-614.	0.9	30
445	Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e510-e516.	0.9	10
446	Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 416-422.	0.9	11
447	A pilot feasibility randomized controlled trial adding behavioral counseling to supervised physical activity in prostate cancer survivors: behavior change in prostate cancer survivors trial (BOOST). <i>Journal of Behavioral Medicine</i> , 2021, 44, 172-186.	1.1	8
448	Nerve-sparing robot-assisted radical prostatectomy: Current perspectives. <i>Asian Journal of Urology</i> , 2021, 8, 2-13.	0.5	28
449	What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 465-481.	2.0	17
450	Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2021, 12, 687-695.	0.5	17
451	Health-Related Quality of Life and Its Associated Factors in Prostate Cancer Patients Who Receive Androgen Deprivation Therapy. <i>Cancer Nursing</i> , 2021, 44, E34-E42.	0.7	5
452	Supported progressive resistance exercise training to counter the adverse side effects of robot-assisted radical prostatectomy: a randomised controlled trial. <i>Supportive Care in Cancer</i> , 2021, 29, 4595-4605.	1.0	6

#	ARTICLE	IF	CITATIONS
453	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. <i>BMJ Open</i> , 2021, 11, e045806.	0.8	12
454	Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients. <i>African Journal of Urology</i> , 2021, 27, .	0.1	5
455	Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. <i>International Journal of Urology</i> , 2021, 28, 765-773.	0.5	10
456	Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. <i>Cancer Medicine</i> , 2021, 10, 3240-3248.	1.3	3
457	Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 661.	1.4	7
458	Measuring Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1373-1382.	0.8	3
459	A drug safety evaluation of enzalutamide to treat advanced prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 741-749.	1.0	3
460	Health outcomes of sexual and gender minorities after cancer: a systematic review. <i>Systematic Reviews</i> , 2021, 10, 183.	2.5	41
461	Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate (FACT-P (Version 4) in Prostate Cancer Patients. <i>Journal of Cancer Education</i> , 2021, , 1.	0.6	0
462	High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 1535-1544.	0.9	11
463	Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 248-255.	2.0	9
464	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. <i>European Journal of Cancer</i> , 2021, 155, 127-135.	1.3	3
465	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Åyr in the CHHiP trial (CRUK/06/016). <i>European Urology Oncology</i> , 2021, 4, 980-992.	2.6	14
466	Knowledge and Attitudes Regarding Surgical Castration in Men Receiving Androgen Deprivation Therapy for Metastatic Prostate Cancer and Their Relationship to Health-Related Quality of Life. <i>Urology</i> , 2021, 155, 179-185.	0.5	4
467	Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types. <i>Value in Health</i> , 2021, 24, 1302-1307.	0.1	5
468	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3
469	Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1230-1239.	5.1	10
470	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	2

#	ARTICLE	IF	CITATIONS
471	Effect of telehealth interventions on quality of life in cancer survivors: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Nursing Studies</i> , 2021, 122, 103970.	2.5	53
472	Evidence-Based Practice in Clinical Behavioral Oncology. , 2014, , 625-672.		2
473	Measuring Quality of Life in Cancer Survivors. , 2007, , 79-110.		17
474	Item Response Theory (IRT): Applications in Quality of Life Measurement, Analysis and Interpretation. , 2002, , 169-185.		8
475	Assessing Quality of Life. , 2000, , 183-198.		1
476	Health-Related Quality of Life. , 2006, , 237-251.		5
477	Prostate Cancer Treatment and Quality of Life. <i>Recent Results in Cancer Research</i> , 2007, 175, 251-265.	1.8	8
478	Quality of Life: Impact of Prostate Cancer and its Treatment. , 2003, , 461-470.		1
479	RECOVERY OF HEALTH RELATED QUALITY OF LIFE IN THE YEAR AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1999, , 515-519.	0.2	17
480	The UCLA Prostate Cancer Index. <i>Medical Care</i> , 1998, 36, 1002-1012.	1.1	790
481	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007, 18, 949-954.	0.7	12
482	The impact of combining human and online supportive resources for prostate cancer patients. <i>Journal of Community and Supportive Oncology</i> , 2017, 15, e321-e329.	0.1	8
483	Effects of Androgen Deprivation on Cerebral Morphometry in Prostate Cancer Patients – An Exploratory Study. <i>PLoS ONE</i> , 2013, 8, e72032.	1.1	46
484	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 511-520.	0.7	7
485	Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalized Prostate Cancer Survivorship Care: Protocol for a Realist Case Study of the Ned App. <i>JMIR Research Protocols</i> , 2017, 6, e197.	0.5	21
486	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-96.	1.3	33
487	Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review. <i>World Journal of Oncology</i> , 2013, 4, 8-17.	0.6	6
488	Group Exercise versus Personal Training for Prostate Cancer Patients: A Pilot Randomized Trial. <i>Journal of Cancer Therapy</i> , 2012, 03, 146-156.	0.1	14

#	ARTICLE	IF	CITATIONS
489	Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors?. World Journal of Clinical Oncology, 2018, 9, 1-12.	0.9	20
490	Evaluating health-related quality of life and priority health problems in patients with prostate cancer: A strategy for defining the role of the advanced practice nurse. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2010, 20, 5-14.	0.1	20
491	A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. PeerJ, 2016, 4, e2613.	0.9	38
492	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. International Journal of Cancer, 2022, 150, 837-846.	2.3	14
493	Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors. Current Oncology, 2021, 28, 3900-3917.	0.9	6
494	Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. Current Oncology, 2021, 28, 3918-3931.	0.9	4
495	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncology Practice, 2022, 18, e442-e451.	1.4	5
496	A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG) Tj ETQq1 1 0.784314 agBT /Over	0.784314	14
497	New Paradigms in the Management of Hormone Refractory Disease. , 2000, , 289-303.		0
499	Health-Related Quality of Life Issues. , 2004, , 373-391.		0
500	The customized monofilament: a new approach to permanent prostate brachytherapy. , 2005, , 591-600.		0
501	Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology, 2005, 23, 8095-8095.	0.8	0
502	Design and Analysis of Quality of Life Data. , 2005, , 247-269.		0
504	Salud y calidad de vida en urologÃa: Aspectos en urologÃa general y oncolÃ3gica. Archivos Espanoles De Urologia, 2009, 62, .	0.1	7
505	Quality of Life in Men Undergoing Radical Prostatectomy for Prostate Cancer. , 2010, , 2875-2885.		0
506	Quality of Life with Localized Prostate Cancer: Japanese Perspectives. , 2010, , 2857-2874.		0
507	Ã%valuation de la qualitÃ© de vie liÃ©e Ã la santÃ© et des problÃ©mes de santÃ© prioritaires chez les patients atteints du cancer de la prostate : stratÃ©gie de dÃ©finition du rÃ©le des infirmiÃ©res en pratique avancÃ©e. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2010, , E1-E11.	0.1	2
508	Summary and Future Directions. , 2012, , 453-483.		0

#	ARTICLE	IF	CITATIONS
509	Outcomes Research. , 2012, , 140-156.e8.		0
510	Effectiveness of Traditional Chinese Medicine in Primary Care. , 0, , .		2
511	Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer. , 2012, , 297-317.		0
514	Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms. Current Clinical Urology, 2014, , 307-320.	0.0	0
516	Principle Component Analysis of Health-Related Quality of Life Measures for Prostate Cancer. Juntendo Medical Journal, 2016, 62, 472-478.	0.1	0
517	Values in Behavioral Medicine. , 2018, , 1053-1068.		0
519	Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. Frontiers in Psychology, 2020, 11, 576459.	1.1	7
520	The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Reviews in Urology, 2001, 3, 113-9.	0.9	17
521	Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. Rehabilitation Oncology, 2016, 34, 27-35.	0.2	6
522	A prospective longitudinal study to evaluate bone health, implication of FRAX tool and impact on quality of life (FACT-P) in advanced prostate cancer patients. American Journal of Clinical and Experimental Urology, 2021, 9, 211-220.	0.4	0
523	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	1.7	3
524	Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 531-538.	2.0	15
525	Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 305-315.	0.4	5
526	Study protocol for the investigation of the clinical effectiveness of a physical activity behaviour change intervention for individuals living with and beyond cancer. Contemporary Clinical Trials Communications, 2022, 26, 100882.	0.5	1
527	Testing the efficacy of a couple-focused, tailored eHealth intervention for symptom self-management among men with prostate cancer and their partners: the study protocol. Trials, 2022, 23, 12.	0.7	2
529	Associations of light physical activity, moderate-to-vigorous physical activity and sedentary behavior with quality of life in men on androgen deprivation therapy for prostate cancer: a quantile regression analysis. Journal of Behavioral Medicine, 2022, 45, 533-543.	1.1	3
530	Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs. Programme Grants for Applied Research, 2022, 10, 1-110.	0.4	6
531	Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study. Journal of Sexual Medicine, 2022, 19, 529-540.	0.3	7

#	ARTICLE	IF	CITATIONS
532	Health Disparities of Sexual Minority Patients Following Prostate Cancer Treatment: Results From the Restore-2 Study. <i>Frontiers in Oncology</i> , 2022, 12, 812117.	1.3	8
533	A systematic review of disease related stigmatization in patients living with prostate cancer. <i>PLoS ONE</i> , 2022, 17, e0261557.	1.1	9
534	The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice. , 2022, , 79-104.		5
535	The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2022, 20, 1-10.	0.7	0
536	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. <i>BMC Cancer</i> , 2022, 22, 177.	1.1	2
537	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 263-279.	1.9	5
538	Prostate Cancer and Sleep Disorders: A Systematic Review. <i>Cancers</i> , 2022, 14, 1784.	1.7	5
539	The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity. <i>Cancer Medicine</i> , 2022, 11, 3425-3436.	1.3	9
540	Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 263-274.	0.7	16
541	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABITUDE study. <i>ESMO Open</i> , 2022, 7, 100431.	2.0	1
542	Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. <i>Anticancer Research</i> , 2022, 42, 87-92.	0.5	0
543	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	1.7	2
544	The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
545	Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). <i>European Urology Focus</i> , 2022, 8, 1607-1616.	1.6	1
546	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449.	2.7	6
547	Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 304-314.	0.8	3
548	Evaluation of health behaviors and overall quality of life in younger adult African American cancer survivors. <i>Cancer Medicine</i> , 0, , .	1.3	0
549	Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4



#	ARTICLE	IF	CITATIONS
550	MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. <i>Lancet Oncology</i> , The, 2022, 23, 910-918.	5.1	32
551	The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. <i>Prostate</i> , 2022, 82, 1237-1247.	1.2	2
552	Exercise training to increase tumour natural killer cell infiltration in men with localised prostate cancer: a randomised controlled trial. <i>BJU International</i> , 2023, 131, 116-124.	1.3	16
553	2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. <i>Acta Oncologica</i> , 2022, 61, 963-971.	0.8	1
554	A Historical and Contemporary Review of Questionnaires Used in the Management of Post-Radical Prostatectomy Patients. <i>Sexual Medicine Reviews</i> , 2022, 10, 681-690.	1.5	0
555	Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the JROCK study. <i>International Journal of Urology</i> , 2022, 29, 1061-1070.	0.5	6
556	Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 146-154.	0.9	3
557	Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the ATERCAB study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1632-1643.	1.0	1
558	Prostate cancer Exercise and Metformin Trial (Pre-EMPT): study protocol for a feasibility factorial randomized controlled trial in men with localised or locally advanced prostate cancer. <i>Pilot and Feasibility Studies</i> , 2022, 8, .	0.5	1
559	Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. <i>Prostate Cancer</i> , 2022, 2022, 1-12.	0.4	3
560	Estetrol Prevents Hot Flashes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study. <i>European Urology Open Science</i> , 2022, 45, 59-67.	0.2	3
561	Effects of oestradiol treatment on hot flashes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial. <i>European Journal of Endocrinology</i> , 2022, 187, 617-627.	1.9	2
562	A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the Consensus-Based Standard for the Selection of Health Measurement Instruments (COSMIN) Methodology. <i>Cancers</i> , 2022, 14, 5120.	1.7	3
563	Quality of life in home-dwelling cancer patients aged 80 years and older: a systematic review. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	1
564	Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study. <i>Quality of Life Research</i> , 0, , .	1.5	1
565	Pain, cancer-related distress, and physical and functional well-being among men with advanced prostate cancer. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	0
566	Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study. <i>International Journal of Translational Medicine</i> , 2022, 2, 618-632.	0.1	0
567	Health-related quality of life the first year after a prostate cancer diagnosis a systematic review. <i>International Journal of Urological Nursing</i> , 2023, 17, 15-28.	0.1	2

#	ARTICLE	IF	CITATIONS
568	Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2023, 64, 869-872.	2.8	4
569	Evaluation of the Effect of Prognostic Variables on the Survival Analysis of Prostate Cancer. <i>Biometrical Letters</i> , 2022, 59, 77-98.	0.4	0
570	Role, race, and place: Prostate cancer disparities in Patients' and Partners' health outcomes and psychosocial factors. <i>Cancer Medicine</i> , 2023, 12, 9857-9867.	1.3	2
571	Unrecognized sexual dysfunction in gay and bisexual men after prostate cancer treatment: the antecedents and impact of anodyspareunia. <i>Journal of Sexual Medicine</i> , 2023, 20, 515-524.	0.3	0
572	Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. <i>Prostate</i> , 2023, 83, 688-694.	1.2	0
573	Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	3
574	Exercise interventions for adults with cancer receiving radiation therapy alone. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	6
575	Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	3
576	Home-based exercise improves quality of life in breast and prostate cancer survivors: A meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0284427.	1.1	1
577	Patients' experiences of completing patient-reported outcomes in clinical trials: An interview study. <i>International Journal of Urological Nursing</i> , 2023, 17, 180-187.	0.1	0
580	Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. <i>Nature Reviews Urology</i> , 2023, 20, 332-355.	1.9	3